Proparacaine

Generic Name
Proparacaine
Brand Names
Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
Drug Type
Small Molecule
Chemical Formula
C16H26N2O3
CAS Number
499-67-2
Unique Ingredient Identifier
B4OB0JHI1X
Background

Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication

Used as a local (ophthalmic) anesthetic.

Associated Conditions
Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Associated Therapies
Local Anaesthesia therapy
Clinical Trials
Related News

Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma

First Posted Date
2022-01-10
Last Posted Date
2023-01-31
Lead Sponsor
The First Affiliated Hospital of Soochow University
Target Recruit Count
40
Registration Number
NCT05182957
Locations
🇨🇳

The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

First Posted Date
2021-12-07
Last Posted Date
2022-03-29
Lead Sponsor
Hellenic Society of Hematology
Target Recruit Count
51
Registration Number
NCT05147493
Locations
🇬🇷

Anticancer Oncology Hospital of Athens "Agios Savvas", Athens, Greece

🇬🇷

University General Hospital of Ioannina, Ioannina, Greece

🇬🇷

Anticancer Hospital of Thessaloniki "Theageneio", Thessaloniki, Greece

and more 3 locations

Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

First Posted Date
2021-12-06
Last Posted Date
2024-06-25
Lead Sponsor
UNC Lineberger Comprehensive Cancer Center
Target Recruit Count
50
Registration Number
NCT05145400
Locations
🇺🇸

University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

🇺🇸

Duke Comprehensive Cancer Center, Durham, North Carolina, United States

🇺🇸

The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

First Posted Date
2021-11-30
Last Posted Date
2024-11-15
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
317
Registration Number
NCT05137054
Locations
🇺🇸

Dana Farber/Harvard Cancer Center, Boston, Massachusetts, United States

🇺🇸

Scripps Clinic Torrey Pines, La Jolla, California, United States

🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

and more 35 locations

Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma

First Posted Date
2021-11-17
Last Posted Date
2023-06-01
Lead Sponsor
Cancer Trials Ireland
Target Recruit Count
43
Registration Number
NCT05123131
Locations
🇩🇰

Aarhus University Hospital, Aarhus, Denmark

🇮🇪

Beaumont Hospital, Dublin, Ireland

🇮🇪

Mater Misericordiae University Hospital, Dublin, Ireland

and more 3 locations

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

First Posted Date
2021-10-29
Last Posted Date
2024-12-16
Lead Sponsor
BeiGene
Target Recruit Count
750
Registration Number
NCT05100862
Locations
🇺🇸

Ucsf Fresno University of California San Francisco Fresno, Fresno, California, United States

🇺🇸

Kaiser Permanente Southern California, Irvine, California, United States

🇺🇸

Cancer and Blood Specialty Clinic, Los Alamitos, California, United States

and more 291 locations

Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

Phase 2
Recruiting
Conditions
Myeloma Multiple
Interventions
Drug: Belantamab mafodotin
Drug: Lenalidomide
First Posted Date
2021-10-25
Last Posted Date
2024-11-20
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
94
Registration Number
NCT05091372
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

First Posted Date
2021-09-20
Last Posted Date
2024-12-10
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
166
Registration Number
NCT05050097
Locations
🇺🇸

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

🇺🇸

Indiana University, Indianapolis, Indiana, United States

🇺🇸

Tennessee Oncology, Nashville, Tennessee, United States

and more 28 locations

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

First Posted Date
2021-08-27
Last Posted Date
2024-10-30
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
47
Registration Number
NCT05025800
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma

First Posted Date
2021-08-20
Last Posted Date
2021-08-27
Lead Sponsor
Puyang Oilfield General Hospital
Target Recruit Count
55
Registration Number
NCT05014100
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy